European Commission backs wider use of Merck's Erbitux

24 December 2013
merck-serono-big-1

Merck Serono, the biopharmaceutical division of Germany’s Merck KGaA (MRK: DE), has gained European Commission approval for the Type II variation to amend the Erbitux (cetuximab) product information, updating the indication for the drug to the treatment of patients with RAS wild-type metastatic colorectal cancer (mCRC).

Shares of Merck, which markets the cancer drug Erbitux outside the USA, advanced 0.9% to 129.85 euros on the news. The drug, in its current indications, generated sales of around $1.2 billion for the German drugmaker last year.

The approval follows the positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP; issued in November 2013) and is based on the totality of data emerging on the role of mCRC RAS tumor status in the benefit–risk profile of the drug. The approval primarily refers to new biomarker data from the OPUS (OxaliPlatin and cetUximab in firSt-line treatment of mCRC) study, the company noted.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical